Molecular Cancer ResearchCancer BiologyPeer-reviewed journal article
MYC-Driven Activation of USP39 Enhances SRSF1 Stability and Promotes PDAC Progression
Benteng MaiD, Xin ZhangiD, Alexander J. KraliD, Neelu SinghiD, Astrid DeschênesiD, Paolo CifaniiD, Youngkyu ParkiD, David Arthur TuvesoniD, Adrian R. KraineriD, Ledong WaniD
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy primarily driven by oncogenic KRAS signaling. The splicing factor SRSF1 plays a key oncogenic role in PDAC, where its tightly regulated expression constrains KRAS-driven signaling under normal conditions, while its upregulation promotes tumorigenesis. SRSF1 expression is regulated in part by proteostasis. However, the precise mechanisms remain unclear. Here, we identify USP39 as a deubiquitinase that interacts with SRSF1 in an RNA-independent manner and stabilizes it by reducing ubiquitination. USP39 expression is elevated in PDAC tumors and precancerous lesions, and correlates with poor patient survival. USP39 knockdown suppresses PDAC cell proliferation and migration, effects that are partially rescued by SRSF1 overexpression. Mechanistically, we show that MYC directly activates USP39 transcription via E-box motifs within its exon 1b promoter, linking MYC-driven transcriptional regulation to post- translational stabilization of SRSF1. Together, these findings define a MYC-USP39-SRSF1 regulatory axis that integrates transcriptional and post-translational mechanisms in PDAC and highlight USP39 as a potential therapeutic target.
- organism: human
- assay: proteomics
- assay: multiome
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: statistical model
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 34th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of KRASG12D feedback regulation involving splicing factor SRSF1 accelerates pancreatic cancer
L. Wan, K.-T. Lin, … A. R. Krainer·bioRxiv·Oct 13, 2021
- Splice-switching ASOs targeting an Alu-derived exon in the AURKA 5'UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer
Alexander J. Kral, Lu Jia, … Adrian R. Krainer·bioRxiv·Apr 14, 2025
- KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
S. L. Tinsley, R. A. Shelley, … B. Allen-Petersen·bioRxiv·Jul 1, 2023
- Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation
Jennifer J. Twardowski, Thomas I. Heist, … Stephano S. Mello·bioRxiv·May 29, 2024
- Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancer
D. K. Cheng, T. E. Oni, … D. A. Tuveson·bioRxiv·Sep 14, 2020
- DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells
Mariana T. Ruckert, R. McKinnon Walsh, … Vanessa S. Silveira·Scientific ReportsPeer-reviewed·Sep 30, 2025